NsGene to initiate Ph Ib trial of AD implant
NsGene AS says that its Clinical Trial Application to start a Phase Ib study of its drug candidate NsG0202 for Alzheimer's disease has been approved by the Swedish Medical Products Agency. The advanced implant product represents a novel treatment method aimed at restoring brain function and not only at alleviating symptoms, the firm noted.
The agent consists of an implantable encapsulated cell biodelivery device that secretes nerve growth factor, which has been shown to have neuroprotective and regenerative effects when delivered to relevant areas of the brain. NsG0202 is aimed at treating the progressive dementia associated with AD.
NsGene expects that the initial three patients will have the EC biodelivery device implanted in the beginning of 2008. In all, six patients will participate in this Phase Ib study, which will run for one year.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze